Next Generation Therapies for Autoimmune and Inflammatory Diseases: Ready for Prime Time or is This Market Immune to Change?
- Danielle M. Marra, MS, MBA, Associate Principal, Cello Health BioConsulting, Previously Defined Health
- David J. Lomb, PhD, Associate Principal, Cello Health BioConsulting, Previously Defined Health
- Gary D. Glick, President & CEO, IFM Therapeutics, LLC
- James Mathew, Professor of Surgery and Microbiology-Immunology, Director of Immune Monitoring Core Comprehensive Transplant Center, Northwestern University, Feinberg School of Medicine
Autoimmune diseases represent the largest pharmaceutical market by revenue globally. Advances in technology and our understanding of the immune system are now ushering in several new immunomodulatory approaches to autoimmune disease, including cell-based therapies, antigen-specific therapies, novel antibody/protein approaches, and even new cytokine/small molecule therapeutics. With the major autoimmune markets – most notably rheumatoid arthritis and psoriasis – near peak maturity and biosimilars on the horizon, it remains to be determined how exactly this new wave of pioneering, yet potentially expensive technology will be used. Are we on the verge of truly paradigm-shifting treatments across autoimmune diseases, or will therapies derived from these novel technologies be relegated only to a handful of niche markets? Join us as we discuss these issues and explore the exciting potential of these innovative approaches to autoimmune diseases.